ESC 365 - New VHD guidelines – What are the implications for the cardiologist?

Open Access

New VHD guidelines – What are the implications for the cardiologist?

Session: How the new European valvular heart disease guidelines could change the treatment of AS patients?

Topic: Aortic valve disease

Speaker: Professor H. Moellmann (Dortmund, DE)

Sponsored by Edwards Lifesciences

Event: ESC Congress 2017

Congress Presentation

About the speaker

Professor Helge Moellmann

St. Johannes-Hospital, Dortmund (Germany)

11 presentations

0 follower

3 more presentations in this session

What is the evidence supporting the new valvular heart disease (VHD) guidelines regarding severe aortic stenosis (AS) treatment?

Speaker: Professor H. Moellmann (Dortmund, DE)

New VHD guidelines – What are the implications for transcatheter aortic valve implantation (TAVI) implanters?

Speaker: Professor H. Moellmann (Dortmund, DE)

Summary: key learnings and conclusion - How the new European VHD guidelines could change the treatment of AS patients?

Speaker: Professor H. Moellmann (Dortmund, DE)

Access the full session

How the new European valvular heart disease guidelines could change the treatment of AS patients?

Speakers: Professor H. Moellmann, Professor H. Moellmann, Professor H. Moellmann, Professor H. Moellmann

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

Related content

Open Access

Session evaluation and key learnings.

29 August 2021

Open Access

Successful treatment of MR and TR patients with differentiated transcatheter technologies.

29 August 2021

Open Access

Supporting HF treatment through transcatheter valve therapy.

29 August 2021

ESC 365 is supported by